# **ModernGraham Valuation**

**Company Name:** 

Company Ticker HSIC

Date of Analysis

Henry Schein, Inc.



7/30/2016

## Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

| 1. Adequate   | e Size of the Enterprise       | Market Cap > \$2Bil  | \$14,874,774,263 Pass |
|---|--------------------------------|--|-----------------------|
| 2. Sufficien  | tly Strong Financial Condition | Current Ratio > 2  | 1.65 Fail             |
| 3. Earnings   | Stability                      | Positive EPS for 10 years prior  | Pass                  |
| 4. Dividend   | Record                         | Dividend Payments for 10 years p   | rior Fail             |
| 5. Earnings   | Growth                         | Increase of 33% in EPS in past 10<br>years using 3 year averages at<br>beginning and end | 109.33% Pass          |
| 6. Moderate   | e PEmg Ratio                   | PEmg < 20  | 31.47 Fail            |
| 7. Moderate   | e Price to Assets              | PB Ratio < 2.5 OR PB*PEmg < 50   | 5.14 Fail             |
| Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor. |                                |  |                       |

| 1. | Sufficiently Strong Financial Condition | Current Ratio > 1.5            | 1.65 Pass |
|----|---|--------------------------------|-----------|
| 2. | Sufficiently Strong Financial Condition | Debt to NCA < 1.1              | 0.52 Pass |
| 3. | Earnings Stability                      | Positive EPS for 5 years prior | Pass      |
| 4. | Dividend Record                         | Currently Pays Dividend        | Fail      |
| 5. | Earnings Growth                         | EPSmg greater than 5 years ago | Pass      |

#### Suitability

| Defensive    | No  |
|--------------|-----|
| Enterprising | Yes |

### Stage 2: Determination of Intrinsic Value

|            | EPSmg                       |            | \$5.75   |
|------------|-----------------------------|------------|----------|
|            | MG Growth Estimate          |            | 7.50%    |
|            | MG Value                    |            | \$135.17 |
|            | MG Value based on 3% Growth |            | \$83.38  |
|            | MG Value based on 0% Growth |            | \$48.88  |
|            | Market Implied Growth Rate  |            | 11.49%   |
| MG Opinion |                             |            |          |
|            | Current Price               |            | \$180.98 |
|            | % of Intrinsic Value        |            | 133.89%  |
|            | Opinion                     | Overvalued |          |
|            | MG Grade                    | C-         |          |

#### Stage 3: Information for Further Research


| Net Current Asset Value (NCAV)                    | -\$5.03 |
|---|---------|
| Graham Number                                     | \$72.61 |
| PEmg  | 31.47   |
| Current Ratio                                     | 1.65    |
| PB Ratio  | 5.14    |
| Current Dividend                                  | \$0.00  |
| Dividend Yield                                    | 0.00%   |
| Number of Consecutive Years of Dividend<br>Growth | 0       |

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

| EPS History      |         | EPSmg History                        |                 |
|------------------|---------|--------------------------------------|-----------------|
| Next Fiscal Year | ** **   | Next Fiscal Vest Estimate            | <b>*- - -</b>   |
| Estimate         |         | Next Fiscal Year Estimate            | \$5.75          |
| Dec2015          | \$5.69  |                                      | \$5.17          |
| Dec2014          | \$5.44  | Dec2014                              | \$4.75          |
| Dec2013          | \$4.93  | Dec2013                              | \$4.28          |
| Dec2012          | \$4.32  | Dec2012                              | \$3.83          |
| Dec2011          | \$3.97  | Dec2011                              | \$3.46          |
| Dec2010          | \$3.49  | Dec2010                              | \$3.05          |
| Dec2009          | \$3.44  | Dec2009                              | \$2.69          |
| Dec2008          | \$2.67  | Dec2008                              | \$2.21          |
| Dec2007          | \$2.36  | Dec2007                              | \$1.90          |
| Dec2006          | \$1.82  | Dec2006                              | \$1.64          |
| Dec2005          | \$1.70  | Dec2005                              | \$1.50          |
| Dec2004          | \$1.43  | Dec2004                              | \$1.33          |
| Dec2003          | \$1.53  | Dec2003                              | \$1.19          |
| Dec2002          | \$1.32  | Dec2002                              | \$0.94          |
| Dec2001          | \$1.01  | Dec2001                              | \$0.66          |
| Dec2000          | \$0.68  | Dec2000                              | \$0.45          |
| Dec1999          | \$0.61  | Balance Sheet Information            | 3/1/2016        |
| Dec1998          | \$0.20  | Total Current Assets                 | \$3,271,003,000 |
| Dec1997          | -\$0.02 | Total Current Liabilities            | \$1,987,504,000 |
| Dec1996          | \$0.47  | Long-Term Debt                       | \$666,283,000   |
|                  |         | Total Assets                         | \$6,600,570,000 |
|                  |         | Intangible Assets                    | \$2,528,360,000 |
|                  |         | Total Liabilities                    | \$3,686,872,000 |
|                  |         | Shares Outstanding (Diluted Average) | 82,739,000      |





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

#### **Recommended Reading:**

| Other<br>ModernGraham<br>posts about the<br>company       | Henry Schein Inc Valuation – February 2016 Update \$HSIC       |  |
|---|--|--|
|   | Henry Schein Inc. Valuation – October 2015 Update \$HSIC       |  |
|   | Henry Schein Inc. Valuation – October 2015 Update \$HSIC       |  |
|   | The Best Companies of the Medical Industry – September 2015    |  |
|   | Henry Schein Inc. Analysis – Initial Coverage \$HSIC           |  |
|   |  |  |
| Other<br>ModernGraham<br>posts about related<br>companies | Quest Diagnostics Inc Valuation – July 2016 \$DGX              |  |
|   | Tenet Healthcare Corp Valuation – July 2016 \$THC              |  |
|   | Laboratory Corp of America Holdings Valuation – July 2016 \$LH |  |
|   | Medtronic PLC Valuation – July 2016 \$MDT                      |  |
|   | Intuitive Surgical Inc Valuation – July 2016 \$ISRG            |  |
|   | Cardinal Health Inc Valuation – July 2016 \$CAH                |  |
|   | PerkinElmer Inc Valuation – July 2016 \$PKI                    |  |
|   | Varian Medical Systems Inc Valuation – July 2016 \$VAR         |  |
|   | St. Jude Medical Inc Valuation – June 2016 \$STJ               |  |
|   | Zimmer Biomet Holdings Inc Valuation – June 2016 \$ZBH         |  |